Posted by: APO | 17 September 2019

“SHORRT” drug-resistant Tuberculosis (TB) treatment on cards

Zimbabwe is set to roll out a Shorter, Highly-effective, Oral Regimen for Rifampicin-resistant Tuberculosis (SHORRT therapy) which reduces the length of treatment for Multi-Drug Resistant Tuberculosis (MDR-TB) from nearly two years, to, nine to 12 months and brings a major improvement in treatment outcomes and quality of life of patients. The nearly two-year-treatment regimen used to treat people… Read more on


%d bloggers like this: